On the face of it, the recent decision by the US Supreme Court in Laboratory Corp. of America v. Metabolite Laboratories seems like a footnote. LabCorp was sued for patent infringement and lost. Upon appeal, the Supreme Court dismissed the case, saying that it should not have granted review. Open and shut, except that the dissent justices opened a can of worms that will be wiggling their way through the field of personalized medicine for years to come.
Advertisement
Survey Series
Institutions
For Advertisers
Biotech Patents Under Fire
What Supreme Court decisions say about threats to the progress of personalized medicine.
|
|||||||||
|
|||||||||
|
